HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Transcept Pharmaceuticals Inc.

Division of Paratek Pharmaceuticals Inc.

Latest From Transcept Pharmaceuticals Inc.

ICAAC 2015: Scrip Connects With Cidara, MerLion And Paratek

Scrip caught up with several biopharma executives on Sept. 18 during the Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and International Congress of Chemotherapy and Infection (ICC) in San Diego to discuss the status of their anti-infective drug development programs.

Dermatology Infectious Diseases

US Capitol Capsule: NIH collaboration sheds light on sleep deprivation's toll

Research has shown that going without 7-8 hours of sleep each night takes a great toll on the human body, resulting in an increased risk for obesity, diabetes, cardiovascular disease, mental illness, cancer growth, Alzheimer's disease and other health problems, according to the National Institutes of Health (NIH).

Metabolic Disorders Gynecology & Urology

Deals Shaping The Medical Industry, September 2014

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced June-August 2014.

BioPharmaceutical Medical Device

Reinvigorated Antibiotics Pipeline Could Produce Four NMEs In 2014

With two novel antibiotics approved and two more under review, 2014 is seeing the end of a long lean period for antibacterial R&D, helped by incentives like Qualified Infectious Disease Product designation. But only one candidate, Cubist’s ceftozolane/tazobactam, addresses the urgent need to target resistant Gram-negative bacteria.

BioPharmaceutical Regulation
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • TransOral Pharmaceuticals Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Paratek Pharmaceuticals Inc.
  • Senior Management
  • Glenn A Oclassen, Pres. & CEO
    Nikhilesh Singh, PhD, SVP, CSO
    John A Kollins, SVP, CBO
  • Contact Info
  • Transcept Pharmaceuticals Inc.
    Phone: (510) 215-3500
    1003 W. Cutting Blvd.
    Ste. 110
    Pt. Richmond, CA 94804